Iron-Based MRI dye could replace risky gadolinium for vein scans
NCT ID NCT07452250
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new MRI contrast agent called ferumoxytol, made from iron nanoparticles, to see if it can safely and effectively image veins in people with vein diseases. Current dyes can be risky for patients with kidney problems, but ferumoxytol may be safer and last longer in the blood. The trial will enroll 50 adults and give them increasing doses to find the smallest amount needed for clear images.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ferumoxytol injection (iron-based contrast agent)
- What this could lead to
- If successful, this could provide a safer alternative to current MRI dyes for diagnosing vein problems, especially for patients with kidney issues.
- What could go wrong
- This is a small, early-phase trial (50 people) focused on imaging quality, not treatment. The iron-based dye may still cause allergic reactions or not work as well as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENOUS DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
RECRUITINGNanjing, Jiangsu, 210008, China